18968-14-4

Basic information

• Product Name: D-(+)Glucuronic acid
• Synonyms: Galactopyranuronicacid, b-D- (8CI)
• CAS NO: 18968-14-4
• Molecular Formula: C₆H₁₀O₇
• Molecular Weight: 194.1394
• Product Categories: Dextrins、Sugar & Carbohydrates
• Mol File: 18968-14-4.mol
• Article Data: 145

Chemical Properties

• Boiling Point: 495.2 °C at 760 mmHg
• Flash Point: 211.1 °C
• Appearance: /
• Density: 1.987 g/cm³
• CAS DataBase Reference: D-(+)Glucuronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: D-(+)Glucuronic acid(18968-14-4)
• EPA Substance Registry System: D-(+)Glucuronic acid(18968-14-4)

Safety Data

• Hazardous Substances Data: 18968-14-4(Hazardous Substances Data)

Usage

General Description

D-(+)Glucuronic acid is a vital biochemical substance involved in numerous biological reactions in the body. D-(+)Glucuronic acid, which is a derivative of glucose, plays a critical role in the detoxification of substances in the liver by conjugating with toxic substances and turning them into water-soluble metabolites that can be safely excreted from the body. It also plays a crucial role in the synthesis of hyaluronic acid, a substance that is key to the health of joints and connective tissue. Additionally, it is a building block of ascorbic acid, or vitamin C. Often, it is provided as a supplement in the form of glucuronic acid or its salts.

Upstream product

• 86438-30-4 copteroside F 
• 91204-06-7 kalopanax-saponin F (3-O-α-arabinopyranosyl-(1->2)-<β-glucopyranosyl-(1->3)>-β-glucuronopyranosyl oleanolic acid 28-O-β-glucopyranosyl ester 
• 90138-26-4 salsoloside E 
• 73977-52-3 2,4-di-O-acetyl-β-methyl-D-galactopyranosideuronic acid γ-lactone 
• 106623-54-5 1-[(α-methyl)phenyl]acetyl-β-D-glucopyranuronic acid 
• 40307-13-9 tri-galacturonic acid 
• 40307-14-0 α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-D-GalpA 
• 40386-95-6 α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-D-GalpA 
• 40386-94-5 α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-α-D-GalpA-(1->4)-D-GalpA 
• 1028100-33-5 3-O-β-D-galactopyranosyl-(1->2)-β-D-glucuronopyranosyl gypsogenin 28-O-β-D-xylopyranosyl-(1->4)-α-L-rhamnopyranosyl-(1->2)-β-D-fucopyranoside 
• 1137205-01-6 3-O-[β-D-glucuronopyranosyl]-30-O-[α-L-arabinopyranosyl(1->2)-β-D-glucopyranosyl] 2β,3β,30-trihydroxyolean-12-en-28-oic acid 
• 1137205-03-8 3-O-[β-D-glucuronopyranosyl]-30-O-[α-L-arabinopyranosyl(1->2)-β-D-glucopyranosyl] 3β,30-dihydroxyolean-12-en-28-oic acid 
• 1137205-04-9 3-O-[β-D-glucuronopyranosyl]-30-O-[β-D-glucopyranosyl] 2β,3β,30-trihydroxyolean-12-en-28-oic acid 
• 1137205-08-3 3-O-[α-L-arabinopyranosyl(1->2)-β-D-glucuronopyranosyl] hederagenin 

Downstream Products

• 153321-67-6 Retinoic Acid glucuronide 
• 35775-49-6 chrysin 7-O-glucopyranuronide 

Relevant articles and documents

Application of bacterial directed enzyme prodrug therapy as a targeted chemotherapy approach in a mouse model of breast cancer

Cancer is the second leading cause of death in the world. Some of the usual cancer treatments include surgery, chemotherapy, and radiotherapy. However, due to low efficacy and side effects of these treatments, novel targeted therapeutic methods are needed. One of the common drawbacks of cancer chemotherapy is off-target toxicity. In order to overcome this problem, many investigations have been conducted. One of the new targeted therapy methods known as bacterial directed enzyme-prodrug therapy (BDEPT) employs bacteria as enzyme carriers to convert a pro-drug to a drug specifically within the tumor site. In the present study, we used Escherichia coli DH5α carrying luxCDABE gene cluster and overexpressing β-glucuronidase for luminescent emission and enzyme expression, respectively. Enzyme expression can lead to the conversion of glycyrrhizic acid as a prodrug to glycyrrhetinic acid, a potent anti-cancer agent. DH5α-lux/βG was characterized and its stability was also evaluated. Bacteria colonization in the tumor site was measured by tissue homogenate preparation and colony counting method. Histopathological studies on the liver, spleen, and tumor were also conducted. According to the results, co-treatment of 4T1, a highly metastatic mouse breast cancer cell line, with GL and DH5α-lux/βG could significantly decrease the IC50 values. Moreover, increased number of bacteria could lead to a dramatic drop in IC50 value. Specific colonization of DH5α-lux/βG was observed in the tumor site compared with other tissues (p 0.0001). Moreover, the biocompatibility evaluation proved that DH5α-lux/βG had no adverse effects on normal tissues. Furthermore, concurrent usage of GL and bacteria in the treatment of induced 4T1 tumors in BALB/c mice significantly delayed tumor growth (p0.001) during 16 days of investigation. Based on these findings, BDEPT might be useful for targeted breast cancer therapy, although further investigations are required to confirm this.

Apigenin Glycosides from Astragalus galegiformis

-

A novel acylated flavonol tetraglycoside and rare oleanane saponins with a unique acetal-linked dicarboxylic acid substituent from the xero-halophyte Bassia indica

In recent years, the scientific interest and particularly the economic significance of halophytic plants has been highly demanding due to the medicinal and nutraceutical potential of its bioactive compounds. A xero-halophyte Bassia indica is deemed to be